VANDA PHARMACEUTICALS INC. Purchase Obligation, to be Paid, Year One
VANDA PHARMACEUTICALS INC. (VNDA) had Purchase Obligation, to be Paid, Year One of $14.00 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Commitment and Contingencies › Purchase Obligation, Fiscal Year Maturity
us-gaap:PurchaseObligationDueInNextTwelveMonths · last filed 2026-08-06
- 2026-06-30: Purchase Obligation, to be Paid, Year One $14.00M.
- 2026-03-31: Purchase Obligation, to be Paid, Year One $12.00M.
- 2025-12-31: Purchase Obligation, to be Paid, Year One $13.50M.
- 2025-09-30: Purchase Obligation, to be Paid, Year One $11.30M.
| Period end | Purchase Obligation, to be Paid, Year One |
|---|---|
| 2026-06-30 | $14.00M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $12.00M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $13.50M 10-K · filed 2026-02-12 |
| 2025-09-30 | $11.30M 10-Q · filed 2025-10-30 |
| 2019-12-31 | $9.20M 10-K · filed 2020-02-26 |
| 2018-12-31 | $5.12M 10-K · filed 2019-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |